What to Do When Verapamil Has Not Achieved Sufficient Attack Reduction in Episodic Cluster Headache
This protocol applies to patients with episodic cluster headache (ICHD-3 3.1.1) who have not responded adequately to Verapamil and require a next preventive step.
Clinical scenario
Episodic cluster headache (ICHD-3 3.1.1) — the pattern seen in the majority of patients — is defined by symptomatic periods lasting 7 days to several months (most commonly 4–12 weeks), separated by symptom-free intervals of at least 3 months.
Previous treatment — insufficient response
Verapamil was the prior preventive step. The target — at least 50% reduction in attack frequency within 2–3 weeks — was not reached. This protocol defines the evidence-based approach taken after that failure.
Next-line approach (partial overview)
Several preventive medication options are available at this stage. The full protocol specifies the selection criteria, monitoring requirements, and the expected timelines to efficacy — which differ by agent and can range from the first week to several weeks.
References
DOI: 10.1111/ene.15956
- the majority of patients experience an episodic pattern (80%, ICHD-3 3.1.1), with symptomatic periods (7 days to several months, most commonly 4-12 weeks) and symptom-free periods of variable duration (minimum of 3 months).
- Lithium is a drug of second choice if verapamil is inefficacious or contraindicated.
- Galcanezumab 300 mg sc every month is recommended in otherwise intractable patients based on one RCT despite missing labeling by the European authorities.
- In a randomized placebo-controlled double-blind trial in episodic cluster headache, galcanezumab 300 mg sc was more efficacious than placebo in reducing weekly attack frequency at the primary endpoint of 3 weeks.
- Clinical efficacy is reached within 1 week.
View source ↗